Market
How will Roche's stock perform post-Poseida acquisition by January 2026?
2
Resolution / Starting Odds
Stock rises more than 10% • 25%
Stock rises 0-10% • 25%
Stock remains flat or declines 0-10% • 25%
Stock declines more than 10% • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
Decrease by more than 20% • 25%
Decrease by 0-20% • 25%
Increase by 0-20% • 25%
Increase by more than 20% • 25%
Highly volatile with no clear trend • 25%
Underperforms the biotech index • 25%
Performs in line with the biotech index • 25%
Outperforms the biotech index • 25%
Decrease • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
Increase by more than 20% • 25%
Remains stable (±10%) • 25%
Increases by more than 50% • 25%
Increases by 30-50% • 25%
Decreases by more than 10% • 25%
Remains 20% or more below pre-announcement level • 25%
Other • 25%
Exceeds pre-announcement level • 25%
Recovers to within 10% of pre-announcement level • 25%
Yes • 50%
No • 50%
Other • 25%
Pfizer • 25%
GSK • 25%
Eli Lilly • 25%